Specific changes of serum proteins in Parkinson's disease patients

PLoS One. 2014 Apr 25;9(4):e95684. doi: 10.1371/journal.pone.0095684. eCollection 2014.

Abstract

The aim of this study is to identify and validate protein change in the serum from PD patients. We used serum samples from 21 PD patients and 20 age-matched normal people as control to conduct a comparative proteomic study. We performed 2-DE and analyzed the differentially expressed protein spots by LC-MS/MS. In PD group 13 spots were shown to be differentially expressed compared to control group. They were identified as 6 proteins. Among these, 3 proteins were confirmed by Western blot analysis. It showed that the frequency of fibrinogen γ-chain (FGG) appeared 70% in PD, which could not be detected in control group. The protein of inter-alpha-trypsin inhibitor heavy chain H4 (ITI-H4) was found to exist two forms in serum. The full size (120 kDa) of the protein was increased and the fragmented ITI-H4 (35 kDa) was decreased in PD group. The ratio of full size ITI-H4 to fragmented ITI-H4 in PD patients was 3.85 ± 0.29-fold higher than in control group. Furthermore, fragmented Apo A-IV (∼ 26 kDa) was mainly detected in control group, while it was rare to be found in PD group. Above findings might be useful for diagnosis of PD. When the expressions of FGG and 120 kDa ITI-H4 are increase, as well as ∼ 26 kDa Apo A-IV disappear would provide strong evidence for PD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apolipoproteins A / blood*
  • Biomarkers / blood
  • Blood Proteins
  • Case-Control Studies
  • Female
  • Fibrinogen / metabolism*
  • Glycoproteins / blood*
  • Humans
  • Male
  • Middle Aged
  • Parkinson Disease / blood*
  • Parkinson Disease / diagnosis
  • Proteinase Inhibitory Proteins, Secretory / blood*

Substances

  • Apolipoproteins A
  • Biomarkers
  • Blood Proteins
  • Glycoproteins
  • ITIH4 protein, human
  • Proteinase Inhibitory Proteins, Secretory
  • apolipoprotein A-IV
  • fibrinopeptides gamma
  • Fibrinogen

Grants and funding

This work was supported by the National 973 Fundamental Project of China, No. 2011CB504100. This study is also supported by National Major Special Project on New Drug Innovation of China (No 2012ZX09301002-004). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.